Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/17458
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: The Australian Cancer Anaemia Survey: a snapshot of anaemia in adult patients with cancer
Author: Seshadri, T.
Prince, H.
Bell, D.
Coughlin, P.
James, P.
Richardson, G.
Chern, B.
Briggs, P.
Norman, J.
Olver, I.
Karapetis, C.
Stewart, J.
Citation: Medical Journal of Australia, 2005; 182(9):453-457
Publisher: Australasian Med Publ Co Ltd
Issue Date: 2005
ISSN: 0025-729X
1326-5377
Statement of
Responsibility: 
Tara Seshadri, H Miles Prince, David R Bell, Paul B Coughlin, Philip P B James, Gary E Richardson, Boris Chern, Peter Briggs, John Norman, Ian N Olver, Chris Karapetis and John Stewart, for the Australia Cancer Anaemia Study (ACAS) Group
Abstract: Objective: To evaluate the frequency and management of anaemia in Australian adults with solid and haematological malignancies. Design: 6-month observational, prospective, multicentre study. Participants: 694 patients recruited from outpatient oncology clinics in 24 hospitals in five Australian states between 9 April 2001 and 31 July 2001. Main outcome measures: Frequency of anaemia (haemoglobin [Hb] level < 120 g/L) at enrolment and over ensuing 6 months, by tumour type, disease status and cancer treatment; anaemia treatment and “trigger” Hb level for this treatment. Results: Participants had median age 60 years, and 61% were women. Prevalence of anaemia at enrolment was 35% (199/562), with 78% of these 199 having mild anaemia (Hb, 100–119 g/L). Frequency of anaemia (either present at enrolment or developing during the study) was 57% overall (323/566), and varied with tumour type, from 49% (lymphoma/myeloma) to 85% (urogenital cancer). Patients who received radiotherapy either in combination or concomitant with chemotherapy were more likely to have anaemia (73%) than those receiving chemotherapy alone (58%) (P = 0.004). Of all chemotherapy patients not anaemic at enrolment, 23% developed anaemia by the second monthly follow-up. Independent predictors for anaemia in chemotherapy patients were low baseline Hb level (odds ratio [OR], 5.4; 95% CI, 2.7–10.9) and use of platinum chemotherapeutic agents (OR, 4.8; 95% CI, 2.1–11.4) (P < 0.001). Anaemia was treated in 41% of patients with anaemia at enrolment — by transfusion (36%), iron (5%) and erythropoietic agents (2%). Frequency of anaemia treatment varied between tumour types, from 19% (breast cancer) to 60% (leukaemia). The mean “trigger Hb” for initiating transfusion was 95 g/L. Conclusions: Anaemia is prevalent among Australian patients with cancer managed in hospital oncology units. Its management varies between tumour types. Many patients do not receive treatment for their anaemia.
Keywords: Australian Cancer Anaemia Study Group
Humans
Neoplasms
Anemia
Incidence
Prevalence
Statistics, Nonparametric
Prospective Studies
Adult
Aged
Aged, 80 and over
Middle Aged
Australia
Female
Male
Description: The document attached has been archived with permission from the editor of the Medical Journal of Australia (09 January 2008). An external link to the publisher’s copy is included.
DOI: 10.5694/j.1326-5377.2005.tb06784.x
Published version: http://www.mja.com.au/public/issues/182_09_020505/ses10667_fm.html
Appears in Collections:Aurora harvest 2
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_17458.pdfPublished version255.92 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.